Clinical trials: Tamoxifen
Normal Healthy Volunteers
Estradiol-Receptor Blockade in Older Men and Women
Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER).
- Trial name
- NCT02271282
- Testing
- Toremifene, GHRH/Ghrelin combined Injection
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, HER2-negative Breast Cancer
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer
This is a non-interventional retrospective cohort study of premenopausal patients with HR+/HER2- breast cancer who are treated in the adjuvant setting with either Tamoxifen, Tamoxifen + Ovarial Function Suppression or Aromatase…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Trial name
- CLEAR-B (NCT05870813)
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- Institut fuer Frauengesundheit
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer
- Trial name
- ADEPT (NCT04569747)
- Testing
- Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
- Where
- 32 sites in United States
- Volunteers
- 393 people
- Sponsor
- Dana-Farber Cancer Institute
Amyotrophic Lateral Sclerosis, ALS Functional Ration Scale
Tamoxifen Treatment in Patients With Motor Neuron Disease
The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS Functional Ration Scale, TAR-DNA-binding Protein-43, Tamoxifen
- Trial name
- NCT02166944
- Testing
- tamoxifen 40 mg daily for one year
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Breast Cancer
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may be an effective way to prevent the recurrence of or…
- Trial name
- NCT00003099
- Testing
- Fenretinide, Tamoxifen Citrate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Hot Flashes
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease.
- Conditions
- Breast Cancer, Hot Flashes, Hot Flushes
- Trial name
- NCT00031720
- Testing
- soy protein, isoflavones, Tamoxifen
- Where
- 14 sites in United States
- Volunteers
- 112 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Healthy
A Drug-drug Interaction Study of DP-R213
The purpose of this study is to learn about the effect of raloxifene on how the body absorbs and processes cholecalciferol and how cholecalciferol affects raloxifene when they are taken together.
- Trial name
- NCT02654093
- Testing
- Cholecalciferol, Raloxifene, Cholecalciferol and Raloxifene co-administration
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Advanced or Metastatic ER+ Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with…
- Trial name
- NCT02734615
- Testing
- LSZ102, LEE011, BYL719
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer
RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast cancer cells. It is not yet known if surgery to remove breast cancer is more effective with or without lymph node removal.
- Trial name
- 10-93 (NCT00002528)
- Testing
- tamoxifen citrate, conventional surgery, radiation therapy
- Where
- 21 sites in Australia, Hungary and 7 more
- Volunteers
- 473 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002967
- Testing
- cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate
- Where
- 108 sites in United States, Canada
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00080743
- Testing
- gefitinib, tamoxifen citrate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ovarian Cancer
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of pamiparib + tamoxifen regimen in epithelial ovarian cancer patients with biochemical recurrence during first-line PARPi…
- Trial name
- NCT05669768
- Testing
- Pamiparib/Tamoxifen
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Androgen Receptor Abnormal, Endometrial Disorder
The Effect of Androgen Receptor Polymorphism on Endometrial Cancer
Endometrial tissue is a hormonal-dependent tissue in both pre- and postmenopausal period. The endometrial cells are expressing receptors for all sex hormones, mainly for estrogen, progesterone and androgens.
- Trial name
- AREC (NCT05157373)
- Testing
- Endometrial sampling and Peripheral blood collection, FSFI Scale
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Nicosia
Breast Cancer
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.
- Trial name
- NCT07349069
- Testing
- HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets
- Where
- 2 sites in China
- Volunteers
- 5,500 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hot Flushes, Hot Flashes
Stellate Ganglion Block (SGB) For Women for Breast Cancer
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on…
- Trial name
- NCT02513329
- Testing
- Bupivicaine, Saline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwestern University
Cancer Related Fatigue
Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study
The overall objective of the REBECCA studies at Stavanger University Hospital (SUH) is to improve the QoL of patients affected by cancer-related fatigue during and after end of treatment, by collecting multi-source real world…
- Trial name
- NCT06120595
- Testing
- REBECCA-assisted intervention 1, REBECCA-assisted intervention 2, Standard follow-up
- Where
- Norway
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Breast Cancer
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor…
- Trial name
- NCT00010140
- Testing
- docetaxel, epirubicin hydrochloride, tamoxifen citrate
- Where
- United Kingdom
- Sponsor
- International Collaborative Cancer Group
Breast Cancer
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002679
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Yale University
Bladder Cancer
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors
- Trial name
- BCTamoxifen (NCT02197897)
- Testing
- Tamoxifen Citrate
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Breast Cancer, Endocrine Therapy
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.
- Conditions
- Breast Cancer, Endocrine Therapy, Endocrine Therapy Adverse Reaction, Vitamin D Deficiency
- Trial name
- NUTRIBREAST (NCT04389424)
- Testing
- Tamoxifen, Exemestane, Anastrozole
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- Instituto Jalisciense de Cancerologia